Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LeMaitre attracts corporate heavyweight to board, audit group

This article was originally published in Clinica

Executive Summary

LeMaitre Vascular (Burlington, Massachusetts), a developer and manufacturer of devices for the treatment of peripheral vascular disease, has appointed John O’Connor to its board of directors; he will also serve as chair of the company’s audit committee. Mr O’Connor retired in 2006, before which he was vice-chairman of services for PricewaterhouseCoopers, where he was a partner for 24 years. The appointment should enable LeMaitre to "regain compliance with the Marketplace Rules of the Nasdaq Stock Market, which require that a majority of the company’s board of directors be independent and that the company’s audit committee be composed of three or more independent directors”. Mr O’Connor’s “strategic acumen” will be an “ideal complement” to those of other board members, said chairman and CEO George LeMaitre.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel